4.7 Article

Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2

Journal

KIDNEY INTERNATIONAL
Volume 83, Issue 5, Pages 825-834

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2012.476

Keywords

apoptosis; PTHrP; Runx2; tubular epithelial cells

Funding

  1. Instituto de Salud Carlos III (ISCIII) [PI050117, RETICEF RD06/0013/1002, REDinREN/RD06/0016]
  2. European Union FEDER [PS09/00447]
  3. Sociedad Espanola de Nefrologia
  4. Comunidad Autonoma de Madrid (CAM) [08.6/0038.1/2000-2, GR/SAL/0415/2004, CIFRA/S-BIO0283/2006]
  5. Ministerio de Ciencia e Innovacion [SAF2002-04356-C02-02, SAF2005-05254]
  6. Programa Juan de la Cierva (Ministerio de Ciencia e Innovacion of Spain)
  7. Programa Sara Borrell (Ministerio de Ciencia e Innovacion of Spain)
  8. Programa Intensificacion Actividad Investigadora (ISCIII/Agencia Lain-Entralgo/CAM)

Ask authors/readers for more resources

Runx2 is a key transcription factor in bone development regulating several processes, including osteoblast apoptosis. The antiapoptotic effects of parathyroid hormone (PTH) in osteoblasts depend on Runx2-mediated transcription of prosurvival genes. In the kidney, PTH-related protein (PTHrP) promotes tubulointerstitial cell survival by activating the PTH/PTHrP type 1 receptor. We found that Runx2 is expressed in renal tubuloepithelial MCT and HK2 cell lines in vitro and in the mouse kidney tubuloepithelium in vivo. The 1-36 amino-acid fragment of PTHrP was found to increase the expression and nuclear translocation of Runx2 in both cell lines in a dose-and time-dependent manner. PTHrP(1-36) protected renal tubuloepithelial cells from folic acid toxicity and serum deprivation, an effect inhibited by a dominant-negative Runx2 construct or a Runx2 siRNA. Furthermore, PTHrP(1-36) upregulated the antiapoptotic proteins Bcl-2 and osteopontin, and these effects were abolished by Runx2 siRNA. Runx2, osteopontin, and Bcl-2 were increased in tubuloepithelial cells from transgenic mice with PTHrP overexpression and in wild-type mice with acute or chronic renal failure. Thus, PTHrP regulates renal tubuloepithelial cell survival via Runx2 in the mammalian kidney.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Urology & Nephrology

Donor liquid biopsy and outcomes in kidney transplantation

Miriam Anfaiha-Sanchez, Emilio Rodrigo Calabia, Alberto Ortiz, Marta Martin-Lorenzo, Gloria Alvarez-Llamas

Summary: Kidney transplantation is the preferred treatment for patients with kidney failure, but ensuring the long-term performance of the transplanted kidney remains challenging. Current research focuses on the risk of primary non-function and delayed graft function as well as recipient survival, making it increasingly difficult to predict if the grafts will provide sufficient kidney function.

CLINICAL KIDNEY JOURNAL (2023)

Editorial Material Urology & Nephrology

Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association

Alberto Ortiz, Christoph Wanner, Ron Gansevoort, Era Council

Summary: The European Society of Cardiology's 2021 guideline on cardiovascular disease prevention has important implications for CV risk screening and kidney health. It emphasizes the need for categorizing individuals based on established conditions such as atherosclerotic CVD, diabetes, hypercholesterolemia, or chronic kidney disease. The inclusion of albuminuria as a step in CVD risk assessment should change clinical practice. Further research is needed to determine the optimal method for assessing CV risk in the general population, including the role of systematic screening for CKD.

CLINICAL KIDNEY JOURNAL (2023)

Review Urology & Nephrology

The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Mehmet Kanbay, Sidar Copur, Dimitrie Siriopol, Abdullah Burak Yildiz, Metehan Berkkan, Raluca Popa, Nuri Baris Hasbal, Alberto Ortiz, Mark A. Perazella

Summary: The development of acute kidney injury (AKI) in cancer patients receiving immune checkpoint inhibitors is associated with an increased risk of mortality.

CLINICAL KIDNEY JOURNAL (2023)

Review Urology & Nephrology

PoCUS in nephrology: a new tool to improve our diagnostic skills

Gregorio Romero-Gonzalez, Joaquin Manrique, Maria F. Slon-Roblero, Faeq Husain-Syed, Rafael De la Espriella, Fiorenza Ferrari, Jordi Bover, Alberto Ortiz, Claudio Ronco

Summary: Point-of-Care Ultrasonography (PoCUS) is a method that adds sonographic imaging to the classical physical examination to help clinicians answer specific questions at the bedside. In recent years, PoCUS has become a valuable tool in clinical practice, improving the accuracy of diagnosis and assessment of renal diseases.

CLINICAL KIDNEY JOURNAL (2023)

Review Cardiac & Cardiovascular Systems

Prevention of cardiorenal damage: importance of albuminuria

Luis M. Ruilope, Alberto Ortiz, Alejandro Lucia, Blanca Miranda, Gloria Alvarez-Llamas, Maria G. Barderas, Massimo Volpe, Gema Ruiz-Hurtado, Bertram Pitt

Summary: Chronic kidney disease (CKD) is a leading cause of death that requires early detection for effective management. The current diagnostic criteria for CKD only identify advanced stages, leaving a 'blind spot' in detection where kidney injury is present but undetectable. Elevated urinary albumin-excretion rate can predict future cardiovascular events. Implementing opportunistic or systematic albuminuria screening and therapy has the potential to improve cardiorenal outcomes and mitigate the projected burden of CKD and cardiovascular diseases in the future.

EUROPEAN HEART JOURNAL (2023)

Review Biochemistry & Molecular Biology

Mitochondrial Dysfunction in the Cardio-Renal Axis

Nerea Mendez-Barbero, Jorge Oller, Ana B. Sanz, Adrian M. Ramos, Alberto Ortiz, Marta Ruiz-Ortega, Sandra Rayego-Mateos

Summary: Cardiovascular disease (CVD) often accompanies chronic kidney disease (CKD), and patients with both conditions have an increased risk of all-cause mortality ranging from 20% to 500%. Maintaining mitochondrial homeostasis appears to be a promising therapeutic strategy for the cardio-renal syndrome (CRS). This review explores the role of mitochondrial dysfunction in cardiovascular and renal diseases and how it may guide the development of novel therapeutic strategies for CRS.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Transplantation

Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis

Beatriz Martin-Carro, Juan F. Navarro-Gonzalez, Alberto Ortiz, Carmine Zoccali, Jurgen Floege, Manuel A. Ferreira, Jose L. Gorriz-Teruel, Natalia Carrillo-Lopez, Sara Panizo, Francesco Locatelli, Markus Ketteler, Gerard M. London, Manuel Naves-Diaz, Cristina Alonso-Montes, Jorge B. Cannata-Andia, Jose L. Fernandez-Martin

Summary: This study found that diabetic patients on haemodialysis have a higher risk of mortality, and high serum parathyroid hormone (PTH) levels are particularly associated with increased mortality risk in diabetic patients.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Biochemistry & Molecular Biology

Interaction of Fabry Disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors

Maria D. Sanchez-Nino, Maria I. Ceballos, Sol Carriazo, Aranzazu Pintor-Chocano, Ana B. Sanz, Moin A. Saleem, Alberto Ortiz

Summary: The interaction between diabetes and Fabry disease may increase the severity of kidney damage by modulating the Gb3 synthesis pathway and downregulating kidney protective genes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Targeting the TWEAK-Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury

Jonay Poveda, Laura Gonzalez-Lafuente, Sara Vazquez-Sanchez, Elisa Mercado-Garcia, Elena Rodriguez-Sanchez, Ines Garcia-Consuegra, Ana Belen Sanz, Julian Segura, Maria Fernandez-Velasco, Fernando Liano, Luis M. Ruilope, Gema Ruiz-Hurtado

Summary: This study establishes the relevance of the TWEAK-Fn14 pathway in cardiac dysfunction linked to CRS3, both as a predictor of mortality in patients with AKI and as a Ca2+ mishandling inducer in cardiomyocytes, and highlights the cardioprotective benefits of TWEAK targeting in CRS3.

JOURNAL OF PATHOLOGY (2023)

Article Transplantation

Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients

Pedro Barrera-Baena, Minerva Rodriguez-Garcia, Enrique Rodriguez-Rubio, Lucia Gonzalez-Llorente, Alberto Ortiz, Carmine Zoccali, Francesco Locatelli, Juergen Floege, Martine Cohen-Solal, Manuel Anibal Ferreira, Markus Ketteler, Gerard Michel London, Jose Luis Gorriz-Teruel, Emilio Sanchez-Alvarez, Miguel Angel Hevia-Suarez, Jesus Maria Fernandez-Gomez, Beatriz Martin-Carro, Carlos Gomez-Alonso, Cristina Alonso-Montes, Jorge Benito Cannata-Andia, Jose Luis Fernandez-Martin

Summary: This study analyzed the association between biochemical parameters of CKD-MBD and bone fragility fractures in hemodialysis patients, and found that hyperphosphatemia is independently and consistently associated with an increased risk of bone fractures.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Chronic kidney disease: the missing concept in the 2019 EULAR/ERA-EDTA recommendations for lupus nephritis

Jorge E. Rojas-Rivera, Sevcan A. Bakkaloglu, Davide Bolignano, Ionut Nistor, Pantelis A. Sarafidis, Sokratis Stoumpos, Mario Gennaro Cozzolino, Alberto Ortiz, ERA ERBP

Summary: Chronic kidney disease (CKD) is diagnosed based on glomerular filtration rate (GFR) and urinary albumin:creatinine ratio (UACR). High cardiovascular risk is associated with moderate or severe CKD. The management recommendations for lupus nephritis (LN) and cardiovascular risk in rheumatic and musculoskeletal diseases do not consider albuminuria or CKD. The authors propose a change in the conceptual framework to treat LN as a cause of CKD and apply evidence from large CKD trials.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Biochemistry & Molecular Biology

CCN2 Activates RIPK3, NLRP3 Inflammasome, and NRF2/Oxidative Pathways Linked to Kidney Inflammation

Sandra Rayego-Mateos, Laura Marquez-Exposito, Pamela Basantes, Lucia Tejedor-Santamaria, Ana B. Sanz, Tri Q. Nguyen, Roel Goldschmeding, Alberto Ortiz, Marta Ruiz-Ortega

Summary: Inflammation is a key characteristic of kidney diseases, and the NLRP3/Inflammasome, RIPK3, and NRF2/oxidative pathways are involved in kidney inflammation regulation. CCN2 is a fibrotic biomarker and mediator of kidney damage, and its role in the NLRP3/RIPK3/NRF2 pathways has not been evaluated.

ANTIOXIDANTS (2023)

Article Urology & Nephrology

Increased expression of SCARF genes favoring SARS-CoV-2 infection in key target organs in CKD

Sol Carriazo, Marta Ribagorda, Aranzazu Pintor-Chocano, Maria Vanessa Perez-Gomez, Alberto Ortiz, Maria Dolores Sanchez-Nino

Summary: Chronic kidney disease, especially diabetic kidney disease, is associated with altered expression of SCARF genes in target organs of COVID-19, potentially increasing susceptibility to SARS-CoV-2 infection.

CLINICAL KIDNEY JOURNAL (2023)

Review Urology & Nephrology

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

Pantelis Sarafidis, Fotini Iatridi, Charles Ferro, Maria-Eleni Alexandrou, Beatriz Fernandez-Fernandez, Mehmet Kanbay, Francesca Mallamaci, Ionut Nistor, Patrick Rossignol, Christoph Wanner, Mario Cozzolino, Alberto Ortiz, ERBP Board

Summary: Chronic kidney disease (CKD) in individuals with type 2 diabetes is a major public health issue. Renin-angiotensin system (RAS) blockers have been the standard treatment, but their effectiveness in reducing cardiovascular events and mortality is limited. Non-steroidal mineralocorticoid receptor antagonists (MRAs) have gained interest due to their better pharmacologic profile. Finerenone, the first compound of this class, has shown promise in reducing kidney disease progression and cardiovascular outcomes in patients with type 2 diabetes.

CLINICAL KIDNEY JOURNAL (2023)

Article Urology & Nephrology

Should we enlarge the indication for kidney biopsy in diabetics? The con part

Alberto Ortiz

Summary: Diabetes is the leading cause of chronic kidney disease (CKD) and more research is needed to understand its distinct phenotypes in patients with CKD. Routine kidney biopsy may be overused in CKD patients with diabetes, and expanding the biopsy criteria may result in more complications. Limited resources should be allocated optimally for early diagnosis and preventive treatment.

CLINICAL KIDNEY JOURNAL (2023)

No Data Available